Osteoarthritis is often driven by untreated cartilage defects that worsen over time. Current surgical options are invasive, inconsistent, and costly. Allovia Cartilage offers surgeons a simple, defect-conforming solution:
Today’s fillers are typically natural, but short-lived — they fade quickly and don’t promote long term structural repair. Other fillers are structural, but made of synthetic, non-biodegradable materials — they integrate, but can’t be reversed.
Allovia is more than two products — it’s a versatile biomaterial platform with broad potential. By preserving the body’s natural blueprint for repair, Allovia can be applied wherever structure, integration, and durability are critical.
Corey is a co-founder and CEO, biomedical engineer, and Donnelly Family Endowed Professor at CU Boulder. He has 15+ years in biomaterials and regenerative medicine, >$20M in funding, and >10 patents/applications.
Allovia says implants and fillers often lack the extracellular matrix (ECM), tissue's natural framework. It says synthetic products fill space temporarily, while animal-derived grafts may integrate poorly, causing fillers to fade, grafts to collapse, and repeat surgeries.
The company develops natural implants that restore lost structure using the body's natural blueprint, enabling integration and lasting functional structure.
